Abstract
Parkinson's disease (PD) is the second most prevalent degenerative disease across the world but the rate for diagnosis at early stage is still low. MicroRNA (miRNA) of cerebrospinal fluid (CSF) was believed to be a potential and promising candidate biomarker to be a more feasible and objective methods. Therefore, we recruited PD patients and controls to analyze the expression of miRNA collected from their CSF by high-throughput sequencing. Since then, 21 miRNAs were detected to be upregulated in PD patients. Furthermore, we tested the level of these miRNA in SH-SY5Y cells treated by MPP+ using quantitative real-time PCR and found the content variation of miR-409-3p, of these 21 miRNAs. Also, more cells survived in the overexpression of the miR-409-3p group when SH-SY5Y cells and mice being built to be the PD model. Conclusively, this study suggests that miRNA in CSF may be one of the biomarkers for early PD diagnosis. In addition, the miR-409-3p was verified to have the protective effect on dopamine neurons, providing a new target and direction for future drug studies on PD treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
